Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.

Fiche publication

Date publication

août 2024

Journal

JHEP reports : innovation in hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MINELLO Anne

Tous les auteurs :
El Messaoudi S, Brichler S, Fougerou-Leurent C, Gordien E, Gerber A, Kortebi A, Lagadic G, Subic-Levrero M, Metivier S, Pol S, Minello A, Ratziu V, Leroy V, Mathurin P, Alric L, Coulibaly F, Pawlotsky JM, Zoulim F, de Lédinghen V, Guedj J,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39100818

Résumé

Bulevirtide is a first-in-class entry inhibitor antiviral treatment for chronic hepatitis D. The viral kinetics during bulevirtide therapy and the effect of combining bulevirtide with pegylated-interferon (Peg-IFN) are unknown.